Gilead Sciences' Best Days May Be Ahead - Here's Why

Gilead Sciences, Inc.'s (NASDAQ:GILD) stock price has fallen 4% over the past two months, which I estimate is mainly due to continued apathy and fear on Wall Street even after progress in tariff negotiations between the U.S. and India and an end to Trump's attacks on Federal Reserve Chairman Jerome Powell. At the same time, on May 23, it published the results of the Phase 3 ASCENT-03 clinical trial in which taking Trodelvy [sacituzumab govitecan] led to a statistically significant improvement in a medical m ...